Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen

Infection and Immunity

Volumn 73, Issue 7, 2005, Pages 4043-4053

  Aloni Grinstein, R ^a   Gat, O ^a   Altboum, Z ^a   Velan, B ^a   Cohen, S ^a   Shafferman, A ^a,b  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^b NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; NEUTRALIZING ANTIBODY; SECRETORY IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG MECHANISM; GASTROINTESTINAL TRACT; GUINEA PIG; HUMORAL IMMUNITY; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; FEMALE; GUINEA PIGS; IMMUNIZATION; RECOMBINANT PROTEINS; SPORES, BACTERIAL; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 21544474979     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.7.4043-4053.2005     Document Type: Article

References (68)

1. Reference deleted.
2. Baillie, L. 2001. The development of new vaccines against Bacillus anthracis. J. Appl. Microbiol. 91:609-613.
3. Barnard, J. P., and A. M. Friedlander. 1999. Vaccination against anthrax attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect. Immun. 67:562-567.
4. Baumler, A., R. M. Tsolis, and F. Heffron. 1996. The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patch. Proc. Natl. Acad. Sci. USA 93:279-283.
5. Bowman, C. C., and J. D. Clements. 2001. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect. Immun. 69:1528-1535.
6. Boyaka, P. N., M. Marinaro, K. Fujihashi, and J. R. McGhee. 2001. Host defense at mucosal surfaces, p. 20-21. In R. R. Rich, T. A. Fleisher, W. T. Shearer, B. L. Kotzin, and H. W. Schroeder (ed.), Clinical immunology. H.W. Moshby, London, United Kingdom.
7. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636-5643.
8. Brachman, P. S., S. H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645.
9. Brossier, F., M. Levy, and M. Mock. 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:661-664.
10. Cataldi, A., M. Mock, and L. Bentancor. 2000. Characterization of Bacillus anthracis strains used for vaccination. J. Appl. Microbiol. 88:648-654.
11. Cohen, S., I. Mendelson, Z. Altboum, D. Kobiler, E. Elhanany, T. Bino, M. Leitner, I. Inbar, H. Rosenberg, Y. Gozes, R. Barak, M. Fisher, C. Kronman, B. Velan, and A. Shafferman. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68:4549-4558.
12. Coulson, N. M., M. Fulop, and R. W. Titball. 1994. Bacillus anthracis protective antigen expressed in Salmonella typhimurium SL 3261 affords protection against anthrax spore challenge. Vaccine 12:1395-1401.
13. Department of Health, Education and Welfare. 1979. Product license 99 1979. Anthrax vaccine adsorbed. Department of Health, Education and Welfare, Washington, D.C.
14. Due, L. H., H. A. Hong, and S. M. Cutting. 2003. Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery. Vaccine 21:4215-4224.
15. Duc, L. H., H. A. Hong, N. Fairwether, E. Ricca, and S. M. Cutting. 2003. Bacterial spores as vaccine vehicles. Infect. Immun. 71:2810-2815.
16. Duc, L. H., H. A. Hong, N. Q. Uyen, and S. M. Cutting. 2004. Intracellular fate and immunogenicity of B. subtilis spores. Vaccine 22:1873-1885.
17. Fellows, P., M. K. Linscott, B. Ivins, M. L. M. Pitt, C. Rossi, P. Gibbs, and A. Friedlander. 2001. Efficacy of human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
18. Ferreira, L. C. S., R. C. C. Ferreira, and W. Schumann. 2005. Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors. Ann. Brazil. Acad. Sci. 77:113-124.
19. Flick-Smith, H., J. E. Eyles, R. Hebdon, E. L. Waters, R. J. Beedham, T. J. Stagg, J. Miller, H. O. Alpar, L. Baillie, and E. D. Williamson. 2002. Mucosal or parental administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70:2022-2028.
20. Fowler, K., B. W. McBride, P. C. Turnbull, and L. Baillie. 1999. Immune correlates of protection against anthrax. J. Appl. Microbiol. 87:305.
21. Friedlander, A., S. Welkos, and B. Ivins. 2002. Anthrax vaccines. Curr. Top. Microbiol. Immunol. 271:33-60.
22. Garmory, H. S., R. W. Titball, K. F. Griffin, U. Hahn, R. Bohm, and W. Beyer. 2003. Salmonella enterica serovar Typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect. Immun. 71:3831-3836.
23. Gat, O., I. Inbar, R. Aloni-Grinstein, E. Zahavy, C. Kronman, I. Mendelson, S. Cohen, B. Velan, and A. Shafferman. 2003. Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines. Infect. Immun. 71:801-813.
24. Gaur, R., P. K. Guptam, A. C. Banerjea, and Y. Singh. 2002. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 20:2836-2839.
25. Guillobel, H. C., J. I. Carinhanha, L. Cardenas, J. D. Clements, D. F. De Almeida, and L. C. S. Ferreira. 2000. Adjuvant activity of a nontoxic mutant of Escherichia coli heat labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain. Infect. Immun. 68:4349-4353.
26. Hartman, A. B., L. Van De Verg, and M. M. Venkatesan. 1999. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect. Immun 67:5841-5847.
27. Hoa, T. T., L. H. Duc, R. Isticato, L. Baccigalupi, E. Ricca, P. H. Van, and S. M. Cutting. 2001. Fate and dissemination of Bacillus subtilis spores in a murine model. Appl. Environ. Microbiol. 67:3819-3823.
28. Hussain, N., and A. T. Florence. 1998. Utilizing bacterial mechanism of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm. Res. 15:153-156.
29. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
30. Isticato, R., G. Cangiano, H. T. Tran, A. Ciabattini, D. Medaglini, M. Oggioni, M. De Felice, G. Pozzi, and E. Ricca. 2001. Surface display of recombinant protein proteins on Bacillus subtilis spores. J. Bacteriol. 183: 6294-6301.
31. Ivins, B., P. Fellows, M. L. M. Pitt, J. Estep, J. W. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784.
32. Ivins, B., M. L. M. Pitt, P. Fellows, J. W. Farchaus, G. E. Benner, D. W. Waag, S. Little, G. W. Anderson, P. Gibbs, and A. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
33. Ivins, B., and S. Welkos. 1986. Cloning and expression of the Bacillus anthracis protective antigen in Bacillus subtilis. Infect. Immun. 54:537-542.
34. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308.
35. Ivins, B., S. Welkos, S. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
36. Ivins, B. E., J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52:454-458.
37. Jendrek, S., S. Little, S. Hem, G. Mitra, and S. Giardina. 2003. Evaluation of the compatibility of a second-generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 21:3011-3018.
38. Jernigan, J. A., D. S. Stephens, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sejvar, C. W. Shepard, M. McConnell, J. Guarner, W. J. Shieh, J. M. Malecki, J. L. Gerberding, J. M. Hughes, and B. A. Perkins. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
39. Little, S., B. Ivins, P. Fellows, M. L. M. Pitt, S. L. W. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for recombinant anthrax vaccine. Vaccine 22:422-430.
40. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175.
41. Liu, S., and S. H. Leppla. 2003. Cell surface tumor endothelium marker 8 cytoplasmic tail-dependent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biochem. 278:5227-5234.
42. Lotter, H., H. Russmann, J. Heesemann, and E. Tannich. 2004. Oral vaccination with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils form amebic liver abscess. Infect. Immun. 72:7318-7321.
43. Marcus, H., R. Danieli, E. Epstein, B. Velan, A. Shafferman, and S. Reuveny. 2004. Contribution of immunological memory to protective immunity conferred by Bacillus anthracis protective antigen-based vaccine. Infect. Immun. 72:3471-3477.
44. Mauriello, E. M. F., L. H. Duc, R. Isticato, G. Cangiano, H. A. Hong, M. De Felice, E. Ricca, and S. M. Cutting. 2004. Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 22:1177-1187.
45. Mazza, P. 1994. The use of Bacillus subtilis as an antidiarrhoeal microorganism. Boll. Chim. Farm. 133:3-18.
46. McBride, B. W., A. Mogg, J. L. Telfer, M. S. Lever, J. Miller, P. C. Turnbull, and L. Baillie. 1998. Protective efficacy of a rccombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16:810-817.
47. McGhee, J. R., M. E. Lamm, and W. Strober. 1999. Mucosal immune responses: an overview, p. 485-490. In P. L. Orga, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee (ed.), Mucosal immunity. Academic Press, New York, N.Y.
48. Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for antigen delivery; potential and limitations. Vaccine 19:1573-1580.
49. Mendelson, I., O. Gat, R. Aloni-Grinstein, Z. Altboum, I. Inbar, C. Kronman, E. Bar-Haim, S. Cohen, B. Velan, and A. Shafferman. 5 February 2005. Efficacious, nontoxigenic Bacilllus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine doi:10.1016 /j.vaccine.2004.11.077.
50. Miller, J., B. W. McBride, R. J. Manchee, P. Moore, and L. Baillie. 1998. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett. Appl. Microbiol. 26:56-60.
51. Moayeri, M., and S. H. Leppla. 2004. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 7:1-6.
52. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
53. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
54. Ogra, P. L., H. Faden, and R. C. Welliver. 2001. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14:430-445.
55. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477.
56. Pezard, C., M. Weber, J. C. Sirard, P. Berche, and M. Mock. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372.
57. Rengel, J., and H. Bohnel. 1995. Preliminary experiments in oral immunization of wildlife against anthrax. Anim. Res. Dev. 41:101-111.
58. Reuveny, S., M. White, Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893.
59. Rhie, G. E., M. H. Roehrl, M. Mourez, R. J. Collier, J. J. Mekalanos, and J. Wang. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA 100:10925-10930.
60. Robinson, K., L. M. Chamberlain, K. M. Schokfleld, J. M. Wells, and R. W. F. Le Page. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15:653-657.
61. Robinson, K., L. M. Chamerlain, M. C. Lopez, C. M. Rush, H. Marcotte, R. W. F. Le Page, and J. M. Wells. 2004. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect. Immun. 72:2753-2761.
62. Sansonetti, P. 2004. War and peace at mucosal surfaces. Nat. Rev. 304:953-964.
63. Schneerson, R., J. Kubler-Kielb, T. Y. Liu, Z. D. Dai, S. H. Leppla, A. Yergey, P. Backlund, J. Shiloach, F. Majadly, and J. B. Robbins. 2003. Poly(γ-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA 100:8945-8950.
64. Singh, Y., K. R. Klimpel, N. Arora, M. Sharma, and S. H. Leppla. 1994. The chymotrypsin-sensitive site, FFD315 in anthrax toxin protective antigens is required for translocation of lethal factor. J. Biol. Chem. 269:29039-29046.
65. Turnbull, P. C. B. 2000. Current Status of immunization against anthrax: old vaccines may be here to stay for a while. Curr. Opin. Infect. Dis. 13:113-120.
66. Ward, S. J., G. Douce, D. Figueiredo, G. Dougan, and B. W. Wern. 1999. Immunogenicity of Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:2145-2152.
67. Welkos S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685.
68. Zeger, N. D., E. Kluter, H. van der Stap, E. van Dura, P. van Dalen, M. Shaw, and L. Baillie. 1999. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J. Appl. Microbiol. 87:309-314.